InvestSMART

IDT Australia Limited (ASX:IDT)

ALERT: Price-sensitive ASX Announcement for IDT
Current share price for IDT : $0.033 -0.008 (-19.51%)+
Announcement
Release
28 Apr 2026 10:03AM
Price at Release
$0.041
Full Release
download
Summary
IDT Australia Limited has provided an update for the March quarter of FY26, highlighting a projected strong finish to the fiscal year. The company anticipates delivering its best fourth-quarter results since its transformation began, despite revenue challenges in the third quarter due to scheduled maintenance. Significant improvements in EBITDA losses are expected, with a forecasted reduction to $1.5 million to $2 million, marking a substantial improvement from FY25. Revenue from the three business verticals is projected to increase, supported by IDT's designation as a Preferred Vendor by Sanofi and favorable US policy changes. The company has also recommissioned major facilities and entered a strategic partnership with Fierce Pharma to enhance its global business reach.
Key Points
  • IDT Australia Limited expects a strong finish to FY26 with its best Q4 result since the transformation program began.
  • FY26 EBITDA loss is forecasted to narrow significantly to $1.5M-$2M, an improvement of 68%-76% compared to FY25.
  • Revenue from the three business verticals is expected to increase to between $15 million and $16 million for FY26.
  • IDT has been designated as a Preferred Vendor by Sanofi, enhancing its business potential.
  • Positive changes in US policy on psychedelics and medicinal marijuana are expected to benefit IDT’s business.
  • IDT has recommissioned key facilities, beginning to realize financial benefits from this multi-year program.
  • The company has partnered with Fierce Pharma to pursue global opportunities in Sterile Fill and API Manufacturing.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.